AC Immune SA (NASDAQ:ACIU) introduced that it’s going to obtain the second ReTain-related milestone cost of CHF 24.6 million below its settlement with Janssen Prescription drugs, a Johnson & Johnson firm. With final December’s milestone cost, this brings the overall milestone funds acquired for ACI-35.030 associated to this trial to CHF 40 million. Supply: Press Launch
